Publications by authors named "L Kanz"
Article Synopsis
- - In 2004, the European Mantle Cell Lymphoma (MCL) Network started a phase III trial comparing two treatments for patients under 66 with advanced-stage MCL: R-DHAP (rituximab plus high-dose chemo) and R-CHOP (standard chemo).
- - After 10.6 years, R-DHAP showed significantly better time to treatment failure compared to R-CHOP, with medians of 8.4 years vs. 3.9 years, and improved overall survival rates, although OS wasn't reached for R-DHAP.
- - The study indicates that some patients with MCL may be cured, although R-DHAP had a slightly higher incidence of
Cytomegalovirus (CMV) reactivation is common after allogeneic hematopoietic cell transplantation (HCT) and may result in fatal CMV disease. Invariant natural killer T (iNKT) cells are potent modulators of the immune system preventing graft-versus-host disease while promoting graft-versus-leukemia effects. It is thought that iNKT cells selectively influence mediators of both innate and adaptive immunity.
View Article and Find Full Text PDFPatients with the pre-leukemia bone marrow failure syndrome called severe congenital neutropenia (CN) have an approximately 15% risk of developing acute myeloid leukemia (AML; called here CN/AML). Most CN/AML patients co-acquire CSF3R and RUNX1 mutations, which play cooperative roles in the development of AML. To establish an in vitro model of leukemogenesis, we utilized bone marrow lin cells from transgenic C57BL/6-d715 Csf3r mice expressing a CN patient-mimicking truncated CSF3R mutation.
View Article and Find Full Text PDF